eHealth Initiative

ehidc.org

eHealth Initiative and Foundation (eHI) is a Washington DC-based, independent, non-profit organization whose mission is to drive improvements in the quality, safety, and efficiency of healthcare through information technology. eHI is a multi-stakeholder collaborative, convening executives from every group in healthcare, to discuss, identify, and share best practices that transform the delivery of healthcare. Working with its membership, eHI advocates for the use of health IT that is practical, sustainable, and addresses stakeholder needs, particularly those of patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

STANDIGM NAMES CARL FOSTER CHIEF BUSINESS OFFICER TO EXPAND STRATEGIC PARTNERSHIPS FOR AI DRUG DISCOVERY

Standigm | August 19, 2022

news image

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the appointment of Chief Business Officer Carl Foster. Based in our U.S. office, Foster will be responsible for expanding strategic partnerships for novel drug target discoveries and first-in-class lead candidate identifications. "Carl has established a reputation for increasing company value. He has significant experience building and growing biotech ...

Read More

Pharmacy Market

TRIALCARD LAUNCHES ENGAGE HCP

TrialCard | August 31, 2021

news image

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Read More

PHARMACY MARKET

TRIS PHARMA SECURES FIRST EX-US AUTHORIZATIONS FOR QUILLIVANT ER ORAL SUSPENSION AND QUILLIVANT ER CHEWABLE TABLET FOR THE TREATMENT

Business Wire | September 26, 2023

news image

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that Health Canada has authorized the use of Quillivant® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12. Quillivant ER will be available as both an oral suspension and chewab...

Read More

Research

DEBIOPHARM INVESTS IN VERISIM LIFE'S $15M SERIES A ROUND TO ADVANCE AI-ENABLED DRUG RESEARCH

Debiopharm International SA | January 11, 2022

news image

Debiopharm a Swiss biopharmaceutical company, announced their co-investment in California-based start-up VeriSIM Life's $15 Million Series A Round to advance their mission to accelerate drug development via technology powered by artificial intelligence. VeriSIM Life's computational platform reduces time and cost of drug development as well as reduces the need for animal testing that, in the vast majority of cases, does not translate well to humans. Debiopharm's co-investment in VeriS...

Read More
news image

Business Insights

STANDIGM NAMES CARL FOSTER CHIEF BUSINESS OFFICER TO EXPAND STRATEGIC PARTNERSHIPS FOR AI DRUG DISCOVERY

Standigm | August 19, 2022

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the appointment of Chief Business Officer Carl Foster. Based in our U.S. office, Foster will be responsible for expanding strategic partnerships for novel drug target discoveries and first-in-class lead candidate identifications. "Carl has established a reputation for increasing company value. He has significant experience building and growing biotech ...

Read More
news image

Pharmacy Market

TRIALCARD LAUNCHES ENGAGE HCP

TrialCard | August 31, 2021

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

Read More
news image

PHARMACY MARKET

TRIS PHARMA SECURES FIRST EX-US AUTHORIZATIONS FOR QUILLIVANT ER ORAL SUSPENSION AND QUILLIVANT ER CHEWABLE TABLET FOR THE TREATMENT

Business Wire | September 26, 2023

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that Health Canada has authorized the use of Quillivant® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12. Quillivant ER will be available as both an oral suspension and chewab...

Read More
news image

Research

DEBIOPHARM INVESTS IN VERISIM LIFE'S $15M SERIES A ROUND TO ADVANCE AI-ENABLED DRUG RESEARCH

Debiopharm International SA | January 11, 2022

Debiopharm a Swiss biopharmaceutical company, announced their co-investment in California-based start-up VeriSIM Life's $15 Million Series A Round to advance their mission to accelerate drug development via technology powered by artificial intelligence. VeriSIM Life's computational platform reduces time and cost of drug development as well as reduces the need for animal testing that, in the vast majority of cases, does not translate well to humans. Debiopharm's co-investment in VeriS...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us